Cannabis Science, Inc. announced that beginning RCD will use the www.iCannabinoid.com online information sharing platform to interact with the general public on all Company projects, Drug Development initiatives, Partnership programs, CBIS Consortium, University Scholarship programs, and all RCD initiatives. Cannabis Science’s primary objective is to research and develop U.S. Food and Drug Administration (FDA)-approved, cannabinoid-based medicine to fight a number of targeted critical ailments, including various Cancers, Neurological Conditions, PTSD, Sleep Deprivation, Chronic Pain, HIV/AIDS, Autism, Parkinson’s Disease, Epilepsy, Chronic Obstructive Pulmonary Disease (COPD), and others. CBIS and its collaborators are well underway on a number of research projects targeting Lung Cancer, Pancreatic Cancer, Neurological conditions including PTSD, Chronic Pelvic Pain, and Oro-bucco-lingual Dyskinesias, to name a few.